Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-923-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$900,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) issued its earnings results on Thursday, May, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.06. The business had revenue of $0.01 million for the quarter. View Selecta Biosciences' Earnings History.
When is Selecta Biosciences' next earnings date?
What price target have analysts set for SELB?
6 brokerages have issued 1-year price targets for Selecta Biosciences' stock. Their predictions range from $4.00 to $33.00. On average, they anticipate Selecta Biosciences' share price to reach $12.50 in the next year. This suggests a possible upside of 431.9% from the stock's current price. View Analyst Price Targets for Selecta Biosciences.
What is the consensus analysts' recommendation for Selecta Biosciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. Mizuho analysts commented, "We believe these readouts will be key drivers for SELB shares in late 2019/early 2020." (5/10/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $7 target price after SELB reported its 4Q18 financial and business update. While we believe SELB’s 1Q19 capital raise addressed some of the near-term headwinds for the stock and should allow the company to further develop its lead program, SEL-212, as a treatment for chronic severe gout, we do think the company must execute well in order to achieve its communicated timelines, which appear somewhat aggressive. As we published recently, the design of the H2H study (SEL-212 vs. Krystexxa) and the fact Krystexxa is being used as monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, even if results are positive. With that said, we remain encouraged after our discussion with management today in which it indicated securing a partnership for its ImmTOR platform remains a priority this year." (3/15/2019)
- 3. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (1/10/2019)
- 4. Canaccord Genuity analysts commented, "We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown." (7/11/2018)
Has Selecta Biosciences been receiving favorable news coverage?
News stories about SELB stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Selecta Biosciences earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Are investors shorting Selecta Biosciences?
Selecta Biosciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,317,726 shares, an increase of 42.6% from the March 29th total of 1,625,693 shares. Based on an average daily trading volume, of 755,506 shares, the days-to-cover ratio is presently 3.1 days. Approximately 6.9% of the shares of the stock are sold short. View Selecta Biosciences' Current Options Chain.
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), Albireo Pharma (ALBO), Savara (SVRA), Arcus Biosciences (RCUS), Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), Achillion Pharmaceuticals (ACHN), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Innate Pharma (IPHYF), Forty Seven (FTSV), Prothena (PRTA), Dynavax Technologies (DVAX) and Catalyst Pharmaceuticals (CPRX).
What other stocks do shareholders of Selecta Biosciences own?
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 50)
- Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 51)
- Dr. John H. Leaman, Exec. Officer (Age 46)
- Dr. Werner Cautreels, Advisor (Age 67)
- Dr. Carsten Brunn, CEO, Pres & Director (Age 48)
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Who are Selecta Biosciences' major shareholders?
Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Man Group plc (8.15%), Wasatch Advisors Inc. (6.53%), BlackRock Inc. (3.78%), Fosun International Ltd (0.98%), Northern Trust Corp (0.94%) and JPMorgan Chase & Co. (0.57%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Siewers, Earl Sands, Lloyd P Johnston, Peter Keller, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.
Which major investors are selling Selecta Biosciences stock?
Which major investors are buying Selecta Biosciences stock?
SELB stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Wasatch Advisors Inc., BlackRock Inc., Fosun International Ltd, AQR Capital Management LLC, Northern Trust Corp, Renaissance Technologies LLC and Charles Schwab Investment Management Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Earl Sands, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $2.35.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $105.25 million and generates $900,000.00 in revenue each year. The company earns $-65,340,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.
What is Selecta Biosciences' official website?
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
